Baidu
map

Cell Res:重大发现助力开发多发性硬化症新疗法

2014-11-27 佚名 生物谷

近日,一篇发表在国际杂志Cell Research上的研究论文中,来自新加坡国立大学的研究人员进行了一项多领域的研究发现了一种新型的免疫细胞,这种免疫细胞或可以帮助有效改善多发性硬化症(MS)的治疗效果。 研究者Xin-Yuan Fu教授表示,我们发现了一种名为TH-GM的新型免疫辅助T细胞,其在免疫系统和神经炎症的发病机制中扮演着重要角色,该项研究为开发新型干预疗法来帮助治疗多发性硬化症非

近日,一篇发表在国际杂志Cell Research上的研究论文中,来自新加坡国立大学的研究人员进行了一项多领域的研究发现了一种新型的免疫细胞,这种免疫细胞或可以帮助有效改善多发性硬化症(MS)的治疗效果。

研究者Xin-Yuan Fu教授表示,我们发现了一种名为TH-GM的新型免疫辅助T细胞,其在免疫系统和神经炎症的发病机制中扮演着重要角色,该项研究为开发新型干预疗法来帮助治疗多发性硬化症非常关键。一种STAT家族蛋白成员STAT5蛋白可以指挥TH-GM来开启对自身抗原的免疫反应从而对白细胞介素IL-7作出反应,进而引发中枢神经系统的神经炎性、发病及损伤;阻断IL-7或STAT5获将为治疗疾病带来新的思路。

MS是个体中枢神经系统常见的一种自身免疫疾病,其在全球影响着250万人的健康,而且在北欧地区广为流行,尽管研究者进行了这么多年的研究,但是MS的发病机制依然尚不清楚,而且该疾病也很难治愈。而本文研究中研究者揭示了IL-7/STAT5介导的信号通路和T辅助细胞介导的病理机制之间的紧密关联。

研究人员在1992年时发现了STAT蛋白家族及其名为JAK-STAT信号通路,感染该路径可以引发许多类型的炎性疾病;如今研究者发现干扰JAK-STAT信号通路的的药物可以治疗许多疾病;而IL-7/STAT5的发现在神经炎性疾病领域可以增加研究人员对药物的开发及新型疗法的研究。最后研究人员希望对TH-GM的生理功能的理解或将帮助开发治疗多种人类自身免疫疾病的新型疗法。

原始出处

Sheng W1, Yang F2, Zhou Y3, Yang H2, Low PY4, Kemeny DM4, Tan P5, Moh A6, Kaplan MH7, Zhang Y4, Fu XY8.STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation.Cell Res. 2014 Nov 21.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1889608, encodeId=ba4b1889608bf, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Mar 05 23:29:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959202, encodeId=3421195920203, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Dec 18 17:29:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868956, encodeId=d33a18689561c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 25 18:29:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982894, encodeId=ad4c19828942c, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Apr 02 09:29:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945433, encodeId=63c2194543304, content=<a href='/topic/show?id=41ef95e62c5' target=_blank style='color:#2F92EE;'>#重大发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95762, encryptionId=41ef95e62c5, topicName=重大发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Sun Apr 26 20:29:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554445, encodeId=24a315544457c, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Nov 29 00:29:00 CST 2014, time=2014-11-29, status=1, ipAttribution=)]
    2015-03-05 jml2009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1889608, encodeId=ba4b1889608bf, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Mar 05 23:29:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959202, encodeId=3421195920203, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Dec 18 17:29:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868956, encodeId=d33a18689561c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 25 18:29:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982894, encodeId=ad4c19828942c, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Apr 02 09:29:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945433, encodeId=63c2194543304, content=<a href='/topic/show?id=41ef95e62c5' target=_blank style='color:#2F92EE;'>#重大发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95762, encryptionId=41ef95e62c5, topicName=重大发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Sun Apr 26 20:29:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554445, encodeId=24a315544457c, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Nov 29 00:29:00 CST 2014, time=2014-11-29, status=1, ipAttribution=)]
    2014-12-18 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1889608, encodeId=ba4b1889608bf, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Mar 05 23:29:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959202, encodeId=3421195920203, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Dec 18 17:29:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868956, encodeId=d33a18689561c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 25 18:29:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982894, encodeId=ad4c19828942c, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Apr 02 09:29:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945433, encodeId=63c2194543304, content=<a href='/topic/show?id=41ef95e62c5' target=_blank style='color:#2F92EE;'>#重大发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95762, encryptionId=41ef95e62c5, topicName=重大发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Sun Apr 26 20:29:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554445, encodeId=24a315544457c, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Nov 29 00:29:00 CST 2014, time=2014-11-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1889608, encodeId=ba4b1889608bf, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Mar 05 23:29:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959202, encodeId=3421195920203, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Dec 18 17:29:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868956, encodeId=d33a18689561c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 25 18:29:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982894, encodeId=ad4c19828942c, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Apr 02 09:29:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945433, encodeId=63c2194543304, content=<a href='/topic/show?id=41ef95e62c5' target=_blank style='color:#2F92EE;'>#重大发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95762, encryptionId=41ef95e62c5, topicName=重大发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Sun Apr 26 20:29:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554445, encodeId=24a315544457c, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Nov 29 00:29:00 CST 2014, time=2014-11-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1889608, encodeId=ba4b1889608bf, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Mar 05 23:29:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959202, encodeId=3421195920203, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Dec 18 17:29:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868956, encodeId=d33a18689561c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 25 18:29:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982894, encodeId=ad4c19828942c, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Apr 02 09:29:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945433, encodeId=63c2194543304, content=<a href='/topic/show?id=41ef95e62c5' target=_blank style='color:#2F92EE;'>#重大发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95762, encryptionId=41ef95e62c5, topicName=重大发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Sun Apr 26 20:29:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554445, encodeId=24a315544457c, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Nov 29 00:29:00 CST 2014, time=2014-11-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1889608, encodeId=ba4b1889608bf, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Mar 05 23:29:00 CST 2015, time=2015-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959202, encodeId=3421195920203, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Dec 18 17:29:00 CST 2014, time=2014-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868956, encodeId=d33a18689561c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 25 18:29:00 CST 2015, time=2015-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982894, encodeId=ad4c19828942c, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Apr 02 09:29:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945433, encodeId=63c2194543304, content=<a href='/topic/show?id=41ef95e62c5' target=_blank style='color:#2F92EE;'>#重大发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95762, encryptionId=41ef95e62c5, topicName=重大发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Sun Apr 26 20:29:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554445, encodeId=24a315544457c, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Nov 29 00:29:00 CST 2014, time=2014-11-29, status=1, ipAttribution=)]
    2014-11-29 kcb074

相关资讯

JAMA Neurol:血清维生素D水平是MS病情有力的预测指标

美国哈佛大学公共卫生学院的Alberto Ascherio博士等人在一项为期5年的应用贝他弗隆治疗多发性硬化症初治患者的随访研究(BENEFIT)中发现,在多发性硬化症(MS)患者中,高维生素D水平与患者较低的病情活动度、核磁共振成像损伤程度、脑萎缩及疾病进展相关。研究结果在线发表在2014年1月的JAMA Neurol杂志上。 465例具有孤立临床症状(首次神经学症

Lancet:他汀类药物或可治疗多发性硬化症(MS-STAT研究)

英国医学杂志《柳叶刀》网站19日刊登一项新成果说,主要用于降血脂的他汀类药物可能对多发性硬化症患者有益,帮助他们减缓脑萎缩,缓解相关病情。 多发性硬化症是造成瘫痪的一大病因,患者大脑和脊髓中的神经受损,导致运动能力、平衡能力和视力下降。据介绍,约有一半患者在患病约10年后,进入症状更为严重的后期阶段,目前尚没有专用药物能有效缓解这一阶段的病情。 英国伦敦大学学院等机构的研究人员报告说,他们共征

Lancet Neurol:Daclizumab能明显降低多发性硬化症(MS)的复发(SELECTION研究)

Daclizumab(赛尼派),一种用于预防肾移植排斥反应的药物,主要作用于CD25受体而抑制免疫系统,但是2009年因业绩不佳而停止销售这款药物。最近一项研究为Daclizumab(赛尼派)带来新的生机,能明显降低多发性硬化症(MS)的复发。这项被命名为SELECT的试验中,由于全球74个中心参与其中,纳入患者18-55岁,复发的多发性硬化患者,患者起始皮下注射150mg和300 mgDacli

Alkermes治疗MS药物进入临床一期研究

最近Alkermes公司开发的治疗多发性硬化症药物ALKS8700进入临床一期研究,公司希望这一产品在未来能够与Biogen公司治疗多发性硬化症的长效药Tecfidera抗衡。公司目前已经招募了125名患者用于检测这一药物的安全性以及患者对药物的耐受剂量等。ALKS8700是一种通过抑制多发性硬化症患者体内富马酸单甲酯进而缓解患者症状的药物。 而目前市场上最畅销的多发性硬化症药物要数Bio

PLOS ONE:抗精神病药或可治疗多发性硬化症

惠灵顿维多利亚大学研究人员发现:使用常见的抗精神病剂,或许可以治疗多发性硬化症(MS)。[pdf free]研究人员Anne La Flamme博士领导的新研究,显示氯氮平和利培酮有潜力成为有效治疗MS的药物。MS是一种神经系统疾病,是由免疫细胞入侵脑部,造成炎症所引起的。它会导致视力受损和协调能力受损,并最终导致瘫痪。虽然疾病治疗药物目前已经上市,但它们往往只对MS患者中某类亚群患者有效,所有这

百健艾迪重磅MS药物Plegridy获FDA批准

百健艾迪(Biogen Idec)8月15日宣布,FDA批准多发性硬化症药物Plegridy(聚乙二醇化干扰素β-1a),用于复发-缓解型多发性硬化症(RRMS)成人患者的治疗,RRMS是多发性硬化症(MS)的最常见类型。Plegridy通过注射笔(Plegridy Pen)皮下注射给药,每2周1次。Plegridy Pen是一种新的预充式即用型自动注射笔。Plegridy是一种皮下注射剂型(su

Baidu
map
Baidu
map
Baidu
map